Android Apple

Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1?

By Yahoo! Finance   |   5 months ago
Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1?

A list of top biotech penny stocks includes Savara Inc. (NASDAQ:SVRA), a company focusing on innovative respiratory disease therapies. SVRA's promising Molgramostim product shows potential in treating rare conditions, with a Strong Buy recommendation and potential 158% price increase.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.